Home

Mark Anthony McCamish

CIK 1390798 · President and CEO · last filed 2026-02-12

Mark Anthony McCamish is a President and CEO who has filed 38 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider disposed of $1.9M of AVDL on Feb 12, 2026. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $266.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$266.7K

Companies

6

Total Filings

38

Lifetime Open-Market Net

-$5.36M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Director 0 $21.64 $0 -$537.1K 13 2026-02-12
RFL Director 60,241 $2.09 $125.9K $0 3 2024-01-08
Vincerx Pharma, Inc. (VINCW) Delisted Director — $1.61 — $0 1 2020-12-28
Forty Seven, Inc. (FTSV) Delisted President and CEO 0 — — -$4.82M 12 2020-04-07
FACT Sr. VP & Chief Medical Officer 13,200 $10.67 $140.8K $0 3 2009-04-06
PDL BIOPHARMA, INC. (PDLI) Delisted SVP & CMO 14,924 — — $0 4 2008-12-19

Recent Filings

38 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-12 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Disp (D) −89,025 -$1.87M EDGAR
2026-02-06 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Gift (G) — $0 EDGAR
2025-07-31 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) +11,000 $0 EDGAR
2024-08-01 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) +11,000 $0 EDGAR
2024-01-08 RFL Grant (A) +27,655 $50.1K EDGAR
2023-12-29 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Sell (S) −75,000 -$1.09M EDGAR
2023-12-28 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Notice (144) −75,000 -$1.09M EDGAR
2023-08-15 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Sell (S) −28,975 -$432.6K EDGAR
2023-08-11 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Notice (144) −28,975 -$431.2K EDGAR
2023-08-03 AVADEL PHARMACEUTICALS PLC (AVDL) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 38
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.